By: Katharine Cimmino, Editor-in-Chief – Attention-deficit/hyperactivity disorder (ADHD) is the most common pediatric psychiatric disorder, and it affects the education, social interactions, and over-all wellbeing of both children and adolescents.1 Symptoms of ADHD can persist into adulthood, and those with this disorder are more likely to suffer from other mental health co-morbidities.2 According to guidelines…

By: Ada Seldin, Staff Editor – The overuse of antipsychotics in the nursing home population for off-label indications continues to impact patient safety. In 2005, the FDA issued a black box warning that stated, “The treatment of behavioral disorders in elderly patients with dementia with atypical antipsychotic medications is associated with increased mortality.” The evidence…

Samad Tirmizi, Pharm. D. Candidate c/o 2014 – Deep vein thrombosis (DVT) is a clot formation that occurs within deep veins, generally in the legs. This can cause swelling and pain due to the engorged vessels, and can eventually result in further complications such as a pulmonary embolism. Patients at high risk for DVT are…

By: Aleena Cherian, Co-Copy Editor [Graphics-Focused] – Attention deficit/hyperactivity disorder (ADHD) is a chronic neurological behavior characterized by persistent patterns of inattention and/or hyperactive behavior, resulting in a wide range of emotional, functional, and neurocognitive impairments.1,2 First line therapy for ADHD consists of stimulant medications together with non-pharmacologic interventions, and has been shown to improve…

By: Nathan Trustman, PharmD Candidate c/o 2013, AMSCOP at LIU – Obesity is defined as having a body mass index (BMI) of 30 kg/m2 or greater. It is thought to be the result of an imbalance between energy intake and energy expenditure, possibly due to a number of genetic and environmental factors.1 It is estimated…

By: Ada Seldin PharmD Candidate c/o 2015 – On April 16th, 2013, the FDA approved the labeling change for the reformulated OxyContin® (oxycodone hydrochloride controlled-release) tablets, made by Pharma L.P. This change reflects the abuse-deterrent properties of the reformulated OxyContin®, which were not present in the original formulation approved by the FDA in 1995. OxyContin®…

By: David Ong, Pharm.D. Candidate c/o 2014 – Our current healthcare system receives much criticism from the press as well as the public. Big pharmaceutical companies (“Big Pharma”) have consistently been characterized as part of the problem. Most of the blame for high drug costs is levied on Big Pharma. One of the criticisms is…

By: Moisey Rafailov, PharmD Candidate c/o 2015 – It was early in the morning on New York’s Route 684 when a car hit a tractor-trailer and continued driving without regard. Imagine that, when later stopped by a police officer, the driver said that the accident was her pharmacist’s fault. What if I were to tell…

By: Elsa Thomas, PharmD Candidate c/o 2013 – Atropine is an anticholinergic used to treat various conditions, such as bradycardia, neuromuscular blockade, mydriasis, nerve agent poisoning, and salivary hypersecretion.1,2  Pharmacologically, it inhibits smooth muscle and glands innervated by postganglionic cholinergic nerves.1,2  It also has functions in the central nervous system (CNS); it could stimulate or…

By: Steve P. Soman – Mirabegron (Mybetriq®), known also by the brand name Betanis®in Japan, is a new once daily oral drug.   First in its class, it is a selective β(3)-adrenoceptor agonist that improves symptoms associated with over active bladder (OAB) such as urinary incontinence, urgency, and urinary frequency by enhancing storage function and relaxing…

By: Neal Shah, Co-Editor-in-Chief – Xerostomia, commonly known as dry mouth, is an anti-muscarinic side effect of numerous medications.  Antidepressants, analgesics, diuretics, and antihistamines have a high propensity to cause xerostomia.1  Xerostomia may also result from Sjogren’s syndrome, Parkinson’s disease, and various chemotherapy agents.2  Traditionally, muscarinic agonists like pilocarpine have been used to reverse xerostomia.…

By: Stanley Saji, Pharm.D. Candidate c/o 2013 – I had a preconceived notion that advanced pharmacy practice experiences (APPEs) were just an application of concepts and therapies learned in pharmacy school.  Little did I know how real APPEs became… During my third rotation, I worked with Dr. Maha Saad, Assistant Clinical Professor in the Department…

By: Lauren Kaveski, Pharm.D. Candidate c/o 2013 – We see proton pump inhibitors (PPIs) used in many medication regimens, but it is unknown whether the majority of patients receive these medications for appropriate durations or indications.  For all labeled indications, other than Zollinger-Ellison Syndrome (a rare condition characterized by damaging gastrin hypersecretion and subsequent hydrochloric…

By: Sum Lam, PharmD, CGP, BCPS, FASCP – Sum Lam, Pharm.D., CGP, BCPS, FASCP is an Associate Clinical Professor in the Department of Clinical Pharmacy Practice at St. John’s University College of Pharmacy and Allied Health Professions.  In conjunction with her full time appointment at St. John’s University, she is a clinical faculty at Geriatric…

By: Dr. Regina Ginzburg – Regina Ginzburg is an Associate Clinical Professor of St. John’s University College of Pharmacy and Allied Health Professions. Her clinical site is at the Institute for Family Health (IFH) where she is an appointed faculty member for the Beth Israel Residency in Urban Family Health. She and Dr. See oversee…

By: Mohamed Dungersi – On January 27, the FDA approved Bydureon® (exenatide extended-release) for use in Type 2 Diabetes Mellitus (T2DM), as an adjunct to diet and exercise.  Bydureon®, a product of Amylin Pharmaceuticals, is a modified formulation of the twice-daily injection, Byetta® (exenatide).  It is the first once-a-week medication for T2DM in the market.…